Adult AIDS Clinical Trials Group (AACTG)
Diane Havlir, MD----Director
Michele Downing, RN--Project Manager
The Adult AIDS Clinical Trials Group (AACTG) is the largest federally sponsored, HIV-related, clinical trials network in the United States. The UCSF unit conducts trials that will advance knowledge in the areas of: antiretroviral and immunomodulatory treatment for HIV disease, the pathogenesis and prevention of AIDS-related opportunistic infections, and metabolic complications of antiretroviral therapy.
The UCSF unit also has a pharmacology laboratory that studies clinically relevant pharmacological issues related to the drugs used to treat HIV disease and its complications. Historically, the most important contributions by the UCSF unit to the national AACTG research effort have been in the areas of national scientific leadership and in subject accrual to trials designed to investigate the natural history and pathogenesis of HIV-related complications and to improve strategies and therapies for preventing and treating these complications.
For more information send email to: actg@php.ucsf.edu or call (415) 514-0550 ext. 354.
HIV Clinical Trials Group (HCTG)
Annie Luetkemeyer, MD--Director
Anna Smith, RN--Study Nurse
The Industry Clinical Trials group conducts Phase I-IV clinical trials in collaboration with industry pharmaceutical companies and UC principle investigators. The studies focus on investigation therapies, including antiretroviral drugs, immunomodulators, therapeutic vaccines and combination treatment therapies.
aluetkemeyer@php.ucsf.edu
(415) 476-4082 ext. 130
Bay Area Perinatal AIDS Center (BAPAC)
Deborah Cohan, MD--Director
BAPAC provides comprehensive obstetrical, gynecological and HIV-specific primary care services for pregnant women, infants and families in Northern California.
The center was established as a Pediatric AIDS Clinical Trials Group site in 1991 and participated in the ground breaking ACTG 076 trial which demonstrated a significant reduction in perinatal transmission associated with the use of AZT during pregnancy, labor and delivery, and during the first six weeks of the infant’s life.
Pregnant women who receive care at BAPAC have extraordinary high rates of follow up and continuity of care post partum, in part because they bring their babies to the same clinic where they themselves receive care.
For more information about the structure and activities of BAPAC, visit the BAPAC Home Page.
BAPAC Contact Information
1001 Potrero Ave., Ward 6D-33
San Francisco, California 94110
Phone: (415) 206-8919
FAX: (415) 206-3626
Community Consortium
Donald I. Abrams, MD--Director
Mary Ellen Kelly---Project Manager
The Community Consortium is a voluntary association of Bay Area HIV care providers that focuses on provider education, clinical research and advocacy. Since its formation in 1985, the Consortium’s membership has grown to more than 200 physicians, nurses and other health care providers who work in private practices, neighborhood clinics, community hospitals, jails and correctional systems, academic medical centers and health maintenance organizations throughout the San Francisco Bay Area.
For more information, visit www.CommunityConsortium.org
Phone: (415) 476-9554
Health Care Evaluation Record Organizer (HERO)
James Kahn, MD----Director
Tracy Nunnery----Technical Director
Charles Hinger----Administrative Manager
Developed by James O. Kahn, MD, and T. Van Nunnery, HERO is a web-based, thin-client electronic medical record (EMR) system and a powerful research database. HERO has been used as the clinic record at Ward 86 since April 2000. In addition to storing patient data, provider information, laboratory values and other tests and observations specific to clinical hospital visits, HERO receives and securely stores information from other databases (laboratory, radiology, pathology). For research, its database can be used to detect changes in care among large populations. HERO is also integrated with myHERO, a publicly-accessible personal health record (PHR) enabling patients to access information online from their own medical record. This complete electronic health record (EHR) system is secure, flexible, extensible, exceeds HIPAA requirements, and is exportable to other clinical care venues.
chinger@php.ucsf.edu
Phone: (415) 514-9370 ext. 502
SCOPE
Steven Deeks, MD----Director
Rebecca Ho----Project Manager
SCOPE, (Study of the Consequences of Protease Inhibitors Era), is a prospective cohort study aimed to understand the biologic mechanisms of disease progression in patients who have failed to achieve complete and durable viral suppression. This study is designed to establish a cohort of HIV infected adults to support scientific evaluation of the long-term clinical, virologic and immunologic consequences of antiretroviral therapy.
A total of 400 adults and adolescents will be enrolled and followed prospectively for 5 years. Subjects will be recruited from the San Francisco General Hospital AIDS Program (Positive Health Clinic), the UCSF AIDS clinic (Moffitt Hospital), and the San Francisco Veteran’s Hospital. An emphasis will be placed on recruiting patients who are willing to commit to long-term follow-up. The cohort consists of HIV infected adults who have been on or off antiretroviral therapy for a minimum of 24 weeks (6 months) with nadir CD4 t-cell count less than 500 and current CD4 t-cell count greater than 50.
Subjects are seen every 4 months. At baseline, demographic information, and past medical history of HIV and non-HIV related is obtained through a direct interview. Detailed questions regarding history of antiretroviral therapy, current HIV related complications, adherence and HIV risk factors are administered at each visit. This information will be confirmed through regular reviews of the medical records. Peripheral blood mononuclear cells, plasma, serum and saliva are also obtained at each visit.
rhoh@php.ucsf.edu
(415) 476-4082 ext. 140
Options
Rick Hecht, MD----Director
The Options Project is a multifaceted study looking at people who have been recently exposed to HIV and may be experiencing primary HIV infection symptoms, and for individuals who have tested HIV positive within a year of receiving an HIV negative test result. The main goal of this project is to see how the use of antiretroviral medications in the early stages of infection affects individual disease progression. Other goals of the Options Project are to look at how HIV is transmitted from one person to another and to address emotional issues involved with a new HIV diagnosis. Options also offers: HIV experienced clinical staff, extensive labwork testing, such as viral load, genotyping and detuned HIV tests, free antiretroviral medications for a specified time, possibility of being involved in other research treatments such as Inter-Leukin 2 or a Strategic Therapy Interruption protocol, and counseling.
For more information about the Options Project, visit the Options Home Page.
AIDS and Cancer Specimen Resource (ACSR)
Michael McGrath, MD----Director
Debra Garcia----Operations Director
AIDS and Cancer Specimen Resource (ACSR) was established by the National Cancer Institute (NCI) to encourage and facilitate basic research on HIV and non-HIV related malignancies. The purpose of the ACSR is to identify and improve access to tissue, blood and other fluid specimens, as well as to provide baseline and clinical data on the specimen. ACSR has recently expanded its specimens to include infected and control specimens from patients with a broad range of diseases. It is hoped that by providing access to these high quality specimens, research in HIV-related malignancies and other areas will be encouraged and facilitated. UCSF is joined in this effort by George Washington University, and Ohio State University. The SFGH-based AIDS Immunobiology Research Laboratory serves as the coordinator of this banking program. The Resource obtains clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS-associated malignancies. These specimens are then linked to a clinical dataset so that experimental results obtained by analysis of specific specimens can be linked to relevant clinical data.
ACSR Contact information
(415) 206-3858
dgarcia@acsr.ucsf.edu
:
Patient Log-in 